Name: Control Bionics (CBL) Short Position History
Creator: Shorted
License: https://creativecommons.org/licenses/by/4.0/

CBL

Health Care Equipment & Services

Control Bionics

Short interest: 0.02%; +0.01 pp 30d; as of 13 Aug 2026
Reported shorts: 105.1K
Shares on issue: 543.089M

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

About Control Bionics

Control Bionics designs, manufactures, and sells augmentative and alternative communication (AAC) technology, enabling individuals with severe communication and physical challenges to interact and control devices using neural signals. Their product suite offers intuitive solutions for speech generation and device control, positioning them in the assistive technology market. The company aims to be a leading global provider of innovative communication and control devices.

Company profile →

Control Bionics (ASX:CBL) has 0.02% of its shares on issue reported as short positions as of 13 Aug 2026, or about 105,057 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.22% in July 2017. CBL is classified in the Health Care Equipment & Services industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Short interest

History & FAQ →

Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.

Strategy fit

How each stock picker strategy reads CBL today

Zanger BreakoutWatchScore 16rank 1445 of 1942
CAN SLIMNot a candidate
Minervini Trend TemplateWatchScore 14rank 1163 of 1716
Crowded-Short BreakoutNot a candidate
Quality compoundersNot a candidate

Prices to 14 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →

CBL fundamentals

In the year to 30 Jun 2026, Control Bionics (ASX:CBL) recorded revenue of A$5.4M and a net loss after tax of A$7.3M. A year earlier it recorded revenue of A$7.0M and a net loss after tax of A$6.1M. Year-on-year growth: revenue −23.3% (FY). Net margin −134.5% (FY). Figures are in AUD, the company's reporting currency; source: ASX (Markit), as at 14 Oct 2026.

Full statements, ratios and filings are on the Financials tab. Not financial advice.

Full financials →